According to the UNAIDS 2021 statistics (United Nations Joint Programme on HIV/AIDS) , there were more than 38.4 million people worldwide living with HIV. Since HIV was first discovered in 1980s, the disease has caused about 34.7 million deaths. However, there are no specific drugs or vaccines, so individuals living with HIV can only be treated with antiviral therapy like antiretroviral drug (ARV), suppressing symptoms and slowing down the process leading to AIDS. Following several HIV-1 treatment regimens, clinical therapy should incorporate multiple ARV drugs to ensure the antiviral effect and reduce the risk of drug resistance. Therefore, many ARV drugs have been studied and developed, including reverse transcriptase inhibitors comprising both nucleoside 2 and non-nucleoside inhibitors , protease inhibitors , integrase inhibitors and fusion inhibitors . Regarding protein targets, the integrase (IN) enzyme stands as a prominent target for medicinal chemistry researchers . This enzyme is produced by a virus with reverse transcription, a process in which viral nucleic acids are catalyzed to form covalent bonds between its genetic information with the DNA (deoxyribonucleic acid) of the host's infected cells . Thus, inhibition of integrase during strand transfer can prevent viral proliferation, and therefore, prolonging the host's lifetime. These inhibitory compounds are called integrase strand transfer inhibitors (INSTIs), and are often in combination IN inhibitors with other HIV medicines to mitigate drug resistance .